Cost of Compounded Anavar: What You'll Actually Pay in 2025

What Is Compounded Anavar and Why Does It Exist?

Oxandrolone is the generic name for the anabolic steroid sold under the brand name Anavar. The FDA approved oxandrolone for adjunctive therapy to promote weight gain after weight loss from surgery, chronic infection, severe trauma, and for muscle wasting in conditions like HIV/AIDS. Pharmaceutical-grade oxandrolone tablets are manufactured by a single primary supplier, which creates frequent supply gaps and very high brand prices. Compounding pharmacies registered under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act may legally prepare oxandrolone for patients with a valid prescription when commercial product is unavailable or a non-standard dose is clinically needed. The FDA maintains a database of registered outsourcing facilities at accessdata.fda.gov.

Oxandrolone is a Schedule III controlled substance under the Controlled Substances Act. The DEA Schedule III classification means it carries moderate-to-low physical dependence potential but requires a written or electronic prescription from a DEA-registered prescriber. A telehealth provider can legally prescribe it in most states, but the prescription must go to a DEA-compliant 503A pharmacy, not to a patient who self-sources it online.

The FDA-approved prescribing information for oxandrolone specifically describes its use in weight regain and protein anabolism in catabolic states. The full prescribing label is available through FDA's DailyMed system. Off-label uses, including lean mass preservation during caloric restriction or GLP-1-assisted weight loss, are common in men's health and anti-aging medicine but fall outside the labeled indication.

How Is Compounded Oxandrolone Priced?

Compounding pharmacies set prices based on four main variables: active pharmaceutical ingredient (API) cost, the dosage form (capsule vs. oral solution vs. troche), volume dispensed per fill, and overhead at the pharmacy tier. Monthly prices in 2025 fall into three tiers.

Tier 1: Low-dose protocols, primarily for women (5 to 10 mg/day) Monthly cost: $60, $120. A 30-day supply of 5 mg capsules from a 503A pharmacy typically runs $65, $85. Oral solutions at 5 mg/mL in a 30 mL bottle (delivering 5 mg/day) cost roughly $60, $75. Prices at this tier have held relatively stable because API sourcing costs for oxandrolone are lower per milligram at small doses.

Tier 2: Mid-range protocols for men, muscle preservation (20 mg/day) Monthly cost: $120, $175. A 30-day supply of 20 mg capsules tends to price between $125 and $165 at established men's health compounding pharmacies. This range reflects higher milligram consumption and slightly elevated compounding labor per unit.

Tier 3: Higher-dose body composition protocols (30 to 40 mg/day) Monthly cost: $175, $250. At 40 mg/day, the API cost per month rises, pushing total pricing to the $200, $250 range at most licensed 503A facilities. Doses above 40 mg/day are rarely prescribed by responsible clinicians because hepatotoxicity risk increases proportionally with dose and duration. A published review in the World Journal of Gastroenterology confirmed dose-dependent hepatocellular injury with oral 17-alpha-alkylated androgens including oxandrolone.

Brand-name pharmaceutical oxandrolone, when available, costs $300, $900+ per month at retail pharmacies without insurance, primarily because it is produced by a near-monopoly supplier. Compounded versions offer meaningful price relief, but only through legal channels.

What Drives Price Variation Between Pharmacies?

Three structural factors cause wide pharmacy-to-pharmacy price differences for the same milligram amount of oxandrolone.

503A vs. 503B registration. Section 503A pharmacies compound for individual patients one prescription at a time. Section 503B outsourcing facilities produce larger sterile or non-sterile batches and face stricter FDA current Good Manufacturing Practice (cGMP) standards. The FDA distinguishes these categories explicitly in its compounding guidance. 503B facilities often charge slightly more per unit but may offer greater quality consistency.

Geographic overhead. A pharmacy operating in a high-cost state passes along facility and licensing costs. Mail-order 503A pharmacies in lower-overhead states sometimes price 15 to 25% lower for the same compound.

Telehealth platform markups. Several men's health or anti-aging telehealth platforms act as intermediaries. They bundle the prescription visit fee and compounding pharmacy cost into a single monthly subscription, typically adding $30, $75 per month over the base pharmacy price. Patients who find their own DEA-compliant prescriber and source directly from a 503A pharmacy often pay less.

Dosage form selection. Oral solutions and troches cost less to compound per milligram than hard-shell capsules because capsule-filling labor and excipient costs are higher. A 10 mg/mL oral solution in propylene glycol or MCT oil often saves $10, $20 per month versus equivalent capsules.

Oxandrolone Dosing for Body Composition: Clinical Context

The body-composition use of oxandrolone is supported by a modest but consistent clinical literature. A randomized controlled trial published in the Journal of Clinical Endocrinology and Metabolism (N=262) found that oxandrolone 20 mg/day significantly preserved lean body mass in men with HIV-associated weight loss versus placebo over 12 weeks. That trial is indexed at PubMed PMID 9467564. A separate study in older men with age-related sarcopenia found 10 mg/day over 12 weeks improved appendicular lean mass and functional strength. PubMed PMID 10619870.

In women, low-dose oxandrolone (2.5 to 10 mg/day) has been studied in burn recovery. A trial published in the Annals of Surgery (N=235 pediatric burn patients) showed sustained lean mass gains with oxandrolone at 0.1 mg/kg/day for 12 months post-burn. Off-label use in healthy women for body recomposition typically stays at 5 to 10 mg/day to minimize virilization risk, which the prescribing label notes includes clitoral enlargement, voice deepening, and acne at higher doses.

The American Association of Clinical Endocrinology (AACE) does not publish a specific guideline on oxandrolone for body composition, but its framework for androgen therapy in women recommends the lowest effective dose for the shortest necessary duration and periodic monitoring of liver enzymes, lipid panels, and hematocrit. The AACE androgen therapy position statement is available at aace.com. Baseline ALT, AST, total cholesterol, LDL, and HDL should be drawn before starting oxandrolone and repeated at 6 to 8 weeks, because oral oxandrolone suppresses HDL by 20 to 30% at therapeutic doses. This lipid effect was quantified in a comparative trial at PubMed PMID 2912402.

Monitoring Costs: The Real Total Price of Oxandrolone Therapy

The sticker price of the compound is only part of what patients spend. A responsible oxandrolone protocol requires:

• Baseline labs before the first prescription (comprehensive metabolic panel, lipid panel, CBC, testosterone, SHBG): $75, $200 depending on whether the patient uses insurance or a cash-pay lab service.
• Follow-up labs at 6 to 8 weeks and every 3 months thereafter: similar cost range.
• Telehealth or in-office prescriber visits: $50, $150/visit, typically quarterly.

Adding monitoring costs, total all-in spending for a compliant oxandrolone protocol runs $150, $400/month depending on tier and lab frequency. Patients who skip monitoring to save money take on real clinical risk, particularly around hepatotoxicity and dyslipidemia. The FDA label for oxandrolone explicitly states that periodic liver function tests are necessary during therapy.

Cost of SARMs vs. Compounded Anavar

SARMs (selective androgen receptor modulators) like ostarine (MK-2866), ligandrol (LGD-4033), and RAD-140 are sometimes marketed as safer, cheaper alternatives to oxandrolone for body recomposition. The price comparison is real. Research-chemical SARMs typically sell for $40, $120/month online. However, the legal and safety picture is entirely different.

No SARM has received FDA approval for any indication. The FDA has issued multiple public warnings about SARMs being sold as dietary supplements, noting they are unapproved drugs with serious risks including liver toxicity, cardiovascular events, and potential harm to the hormonal axis. The FDA's 2017 safety communication on SARMs is posted at fda.gov. A 2023 case series in the American Journal of Case Reports documented liver injury requiring hospitalization in three men who used ostarine purchased online. PubMed PMID 37089054.

Third-party testing of commercial SARM products has repeatedly found dosing inaccuracies and contamination. A 2017 study published in JAMA (N=44 SARM products) found that only 52% contained the labeled compound, 39% contained an unlisted active drug, and 25% contained substances not listed at all. PMID 28448649. Paying $60/month for a product that may not contain what the label says represents a different category of financial and health risk than paying $150/month for a compounded Schedule III drug from a DEA-audited 503A pharmacy.

The World Anti-Doping Agency (WADA) prohibits all SARMs in sport. WADA's 2024 prohibited list is maintained at wada-ama.org. For competitive athletes, even a contaminated supplement can trigger a positive test that ends a career, regardless of intent.

From a purely cost-adjusted-for-risk standpoint, compounded oxandrolone through a licensed prescriber is a more legally defensible option for patients who qualify medically, even though the upfront price is higher than most SARMs.

GLP-1 Plus Oxandrolone: An Emerging Protocol and Its Costs

A growing number of weight-loss-focused clinicians prescribe oxandrolone alongside GLP-1 receptor agonists like semaglutide or tirzepatide to preserve lean mass during rapid weight loss. Semaglutide at 2.4 mg/week (Wegovy) produced 14.9% mean body weight loss at 68 weeks versus 2.4% in the placebo arm of STEP-1 (N=1,961), as published in the New England Journal of Medicine. PMID 33567185. A common criticism of GLP-1-driven weight loss is that a significant fraction of the lost weight comes from lean tissue. A body composition substudy of SURMOUNT-1 (N=670 with DEXA) reported that approximately 39% of total weight lost on tirzepatide came from lean mass.

Clinicians adding oxandrolone to a GLP-1 protocol typically prescribe it during the active weight-loss phase (months 3, 12) at doses of 10 to 20 mg/day in men and 5 to 10 mg/day in women. The combined monthly cost of this protocol runs approximately:

• Compounded semaglutide or tirzepatide: $200, $400/month (503B pharmacy, current 2025 pricing)
• Compounded oxandrolone: $80, $175/month depending on dose
• Shared labs and prescriber visit, amortized monthly: $50, $100

Total combined protocol: $330, $675/month. That sits below the $800, $1,200/month cash price for brand-name GLP-1 therapy alone at most retail pharmacies, making the combination clinically attractive for appropriately selected patients. The FDA's framework for 503B outsourcing facilities governs quality standards for compounded injectables used in these combined protocols.

How to Verify a Compounding Pharmacy Is Legitimate

Patients sourcing compounded oxandrolone should verify three things before sending payment.

First, confirm the pharmacy holds a current 503A or 503B registration. The FDA publishes a list of registered 503B outsourcing facilities updated monthly. That searchable database is at fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities. For 503A pharmacies, the relevant state board of pharmacy license should be verifiable on the state regulator's website.

Second, confirm the pharmacy requires a valid DEA-registered prescriber's prescription before dispensing. Any website that ships oxandrolone without a prescription is operating illegally and likely selling counterfeit or adulterated product. The DEA's online pharmacy regulations under 21 CFR Part 1306 prohibit dispensing Schedule III substances without a valid prescription.

Third, ask whether the pharmacy provides a certificate of analysis (COA) from an independent third-party testing lab confirming API identity and potency for each lot. Reputable 503A and 503B pharmacies provide COAs on request. A pharmacy that refuses is a red flag regardless of its marketing claims.

Who Qualifies for a Compounded Oxandrolone Prescription?

Clinicians writing oxandrolone prescriptions in a legitimate telehealth or in-office practice look for one or more of the following medical justifications:

• Documented involuntary weight loss exceeding 10% of body weight from a catabolic condition.
• HIV wasting syndrome or other immunodeficiency-associated muscle loss (the labeled FDA indication).
• Sarcopenia with functional impairment in men over 60, confirmed by DEXA or grip-strength testing.
• Active GLP-1 therapy with documented lean mass decline on follow-up body composition testing.
• Turner syndrome in pediatric patients (a separate labeled indication per the FDA prescribing information).

Healthy adults who simply want to add muscle mass without a documented medical indication are not appropriate candidates under FDA-approved or standard off-label practice. The Endocrine Society's clinical practice guideline on androgen deficiency in men specifies that androgens should not be prescribed to men without confirmed hypogonadism solely for performance enhancement. The same principle applies to anabolic agents like oxandrolone.

What the HealthRX Medical Team Looks for Before Prescribing

Before any HealthRX provider writes a compounded oxandrolone prescription, the patient chart must document a qualifying clinical indication, a current comprehensive metabolic panel (CMP) with ALT/AST within the past 60 days, a lipid panel, and either a DEXA scan or validated lean mass estimate. Patients with active liver disease, uncontrolled hyperlipidemia, or a history of androgen-sensitive malignancy are excluded. The prescription is written for no more than a 90-day supply at a time, with a mandatory lab recheck before refill. This protocol aligns with the monitoring framework published in the Endocrine Society's testosterone therapy guidelines and the FDA-approved prescribing label, both of which specify periodic hepatic and lipid evaluation. Endocrine Society guideline, PubMed PMID 20525905.